XRCC3 is a promising target to improve the radiotherapy effect of esophageal squamous cell carcinoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1349-7006|106|12|1678-1686

ISSN： 1347-9032

Source： Cancer Science, Vol.106, Iss.12, 2015-12, pp. : 1678-1686

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

HOXC13 promotes proliferation of esophageal squamous cell carcinoma via repressing transcription of CASP3

By  

Cancer Science, Vol. 109, Iss. 2, 2018-02 ,pp. : 317-329

John Wiley & Sons Inc

Access to resources Recommend Favorite

Somatic alteration and depleted nuclear expression of BAP1 in human esophageal squamous cell carcinoma

By  

Cancer Science, Vol. 1347-9032, Iss. 9, 2015-09 ,pp. : 1118-1129

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomized study of low‐dose versus standard‐dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303)

By  

Cancer Science, Vol. 106, Iss. 4, 2015-04 ,pp. : 407-412

John Wiley & Sons Inc

Access to resources Recommend Favorite

Somatic alteration and depleted nuclear expression of BAP1 in human esophageal squamous cell carcinoma

By  

Cancer Science, Vol. 106, Iss. 9, 2015-09 ,pp. : 1118-1129

John Wiley & Sons Inc

Access to resources Recommend Favorite

PRIMA‐1 induces p53‐mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation

By  

Cancer Science, Vol. 109, Iss. 2, 2018-02 ,pp. : 412-421

John Wiley & Sons Inc

Access to resources Recommend Favorite